Edition:
India

Sartorius Stedim Biotech SA (STDM.PA)

STDM.PA on Paris Stock Exchange

88.75EUR
22 Jun 2018
Change (% chg)

€-0.80 (-0.89%)
Prev Close
€89.55
Open
€89.60
Day's High
€89.90
Day's Low
€88.75
Volume
70,488
Avg. Vol
57,726
52-wk High
€90.75
52-wk Low
€50.13

Latest Key Developments (Source: Significant Developments)

Sartorius Stedim Biotech And Siemens Sign Long-Term Cooperation Agreement In Area Of Automation
Tuesday, 12 Jun 2018 

June 12 (Reuters) - Sartorius Stedim Biotech Sa ::SARTORIUS STEDIM BIOTECH AND SIEMENS SIGN LONG-TERM COOPERATION AGREEMENT IN AREA OF AUTOMATION.SIEMENS BECOMES A PREFERRED SUPPLIER FOR AUTOMATION SOLUTIONS.PRODUCT PORTFOLIO OF SARTORIUS STEDIM BIOTECH TO FEATURE A GLOBALLY STANDARDIZED AUTOMATION PLATFORM IN FUTURE.PRODUCT PORTFOLIO OF SARTORIUS STEDIM BIOTECH TO FEATURE A GLOBALLY STANDARDIZED AUTOMATION PLATFORM IN FUTURE.  Full Article

Sartorius Stedim Biotech Net Profit Up at 47.1 Million Euros
Tuesday, 24 Apr 2018 

April 24 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::CONFIRMS 2018 TARGETS.IN Q1 INCREASED ITS SALES REVENUE IN CONSTANT CURRENCIES BY 9.8% (REPORTED 4.6%) TO 281.1 MILLION EUROS..Q1 UNDERLYING EBITDA INCREASED 3.0%, AND REACHED 74.0 MILLION EUROS.Q1 CAPEX RATIO OF 2018 WAS 9.2%.Q1 ORDER INTAKE INCREASED BY 9.0% IN CONSTANT CURRENCIES (REPORTED 3.9 PERCENT).EQUITY RATIO ET END OF PERIOD 62.8% (DEC. 31, 2017: 62.6%).Q1 EBITDA EUR 74.0 MILLION VERSUS EUR 71.9 MILLION YEAR AGO.Q1 NET PROFIT EUR 47.1 MILLION VERSUS EUR 44.0 MILLION YEAR AGO.  Full Article

Sartorius Stedim Biotech And Penn State University Entered Into Collaborative Partnership
Monday, 16 Apr 2018 

April 16 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::SARTORIUS STEDIM BIOTECH AND PENN STATE UNIVERSITY ENTERED INTO COLLABORATIVE PARTNERSHIP TO ADVANCE MULTIDISCIPLINARY TEACHING AND RESEARCH IN BIOTECHNOLOGY.  Full Article

Abzena Selects Sartorius Stedim Biotech To Equip Sites In San Diego And Bristol
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::ABZENA SELECTS SARTORIUS STEDIM BIOTECH TO EQUIP US BASED DVLPT AND MANUFACTURING SITES IN SAN DIEGO AND BRISTOL.TO EQUIP ABZENA INTEGRATED CDMO FACILITIES IN BRISTOL AND SAN DIEGO.EQUIP SAN DIEGO PROCESS DVLPT LAB WITH AMBR250, ENABLING FAST SCALE UP TO 500L INITIALLY AND LATER TO 2000L SCALE SINGLE-USE BIOREACTOR.WILL PROVIDE BOTH FACILITIES WITH END-TO-END PROCESS SOLUTIONS IN SINGLE-USE (SU) FORMAT.  Full Article

Sartorius Stedim Biotech 9-month EBITDA up at ‍​216.2 million euros
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::9 MONTHS SALES REVENUE EUR 806.5 ‍​ MILLION VERSUS EUR 785.1 MILLION YEAR AGO.9 MONTHS EBITDA EUR ‍​216.2 MILLION VERSUS EUR 214.1 MILLION YEAR AGO.9 MONTHS NET PROFIT EUR 132.1‍​ MILLION VERSUS EUR 131.3 MILLION YEAR AGO.‍FULL-YEAR 2017 GUIDANCE ADJUSTED, MID-TERM OUTLOOK CONFIRMED​.‍FOR 2017 NOW EXPECTS THAT SALES REVENUE GROWTH WILL REACH APPROX. 4% IN CONSTANT CURRENCIES ​.‍FOR 2017 UNDERLYING EBITDA MARGIN WILL BE APPROX. AT PRIOR-YEAR LEVEL OF 27.5%​.FOR 2017 ‍CAPITAL EXPENDITURES ARE EXPECTED TO BE AT UPPER END OF BANDWIDTH OF AROUND 10% TO 13% OF SALES.​.  Full Article

Sartorius Stedim Biotech cuts 2017 outlook
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::REPORTED ON MONDAY 9-MONTH SALES REVENUE EUR 806 MLN, UP 3.3 PCT IN CONSTANT CURRENCIES.9-MONTH UNDERLYING EBITDA MARGIN AT 26.8 PCT VS 27.3 PCT YEAR AGO.IN 2017 SEES INCREASE OF SALES REVENUE IN CONSTANT CURRENCIES BY ABOUT 4 PCT (VS PREVIOUS GUIDANCE FROM ABOUT 8 PCT TO 12 PCT) .IN 2017 SEES UNDERLYING EBITDA MARGIN IN CONSTANT CURRENCIES AT ABOUT THE PRIOR-YEAR LEVEL OF 27.5 PCT (VS PREVIOUS GUIDANCE ABOUT +0.5 PCT POINTS VS FY 2016).CONFIRMS MID-TERM TARGETS.  Full Article

Sartorius Stedim Biotech H1 revenue up 20.6 pct to 508.8 million euros
Monday, 25 Jul 2016 

Sartorius Stedim Biotech SA : H1 revenue 508.8 million euros ($558.41 million) versus 422.0 million euros year ago . H1 net profit 83.5 million euros versus 62.9 million euros year ago . H1 EBITDA 136.4 million euros versus 106.5 million euros year ago . Outlook for 2016 raised . Sales revenues are now expected to increase by about 17 pct to 20 pct in constant currencies .Underlying EBITDA margin is projected to rise about 1.5 percentage points in constant currencies.  Full Article

Sartorius Stedim Biotech Acquires U.S. start up Ksep systems
Wednesday, 6 Jul 2016 

Sartorius Stedim Biotech : Acquires U.S. start up Ksep systems . Transaction values Ksep at around $28 million and will be closed by end of July 2016 .Ksep holdings, inc. Expected to achieve significant double-digit growth and to generate around $7 million sales revenues and a strong double-digit EBITDA margin in 2016.  Full Article

BRIEF-Sartorius Stedim Biotech Net Profit Up at 47.1 Million Euros

* IN Q1 INCREASED ITS SALES REVENUE IN CONSTANT CURRENCIES BY 9.8% (REPORTED 4.6%) TO 281.1 MILLION EUROS.